SCHEMBL1712644

SCHEMBL1712644

COC(=O)c1cc[c]cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.42
NR4A2 P43354 4/20 0.41
LMNA P02545 3/20 0.40
TSHR P16473 2/20 0.40
GAA P10253 2/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
ALDH1A1 P00352 4/20 0.39
HSD17B10 Q99714 2/20 0.39
CFTR P13569 1/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 3/20 0.38
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA7 P43166 2/20 0.38
CA9 Q16790 2/20 0.38
CA14 Q9ULX7 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5465624 0.85 ABL1 (0.42) ABL1NR4A2LMNATSHRGAA
SCHEMBL130031 0.82 TSHR (0.44) ABL1LMNATSHRGAAALDH1A1
SCHEMBL11474155 0.81 EGFR (0.35) LMNAKMT2AMEN1CA12CA1
SCHEMBL3334103 0.79 LMNA (0.55) LMNATSHRGAAALDH1A1HSD17B10
SCHEMBL4288278 0.79 TSHR (0.41) ABL1NR4A2LMNATSHRGAA
SCHEMBL441463 0.79 MAPK1 (0.33) LMNAALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL1355068 0.78 ALDH1A1 (0.41) LMNATSHRGAASLC6A4SLC6A3
SCHEMBL1266916 0.78 SMN1; SMN2 (0.40) LMNAGAAALDH1A1KMT2ASMN1; SMN2
SCHEMBL6070132 0.78 ALDH1A1 (0.56) ABL1LMNATSHRGAASLC6A3
SCHEMBL7421653 0.78 TSHR (0.40) ABL1LMNATSHRGAASLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102180874-A Synthetic process method for azabicyclo medicinal intermediates ACCELA CHEMBIO INC 2011-09-14 CN claimed
CN-102101861-A Synthesis and process method of nitrogen-containing bis-heterocyclic medicine intermediate ACCELA CHEMBIO CO LTD 2011-06-22 CN claimed
US-20200308109-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2020-10-01 US disclosed
EP-2900645-B1 HERBICIDAL AND FUNGICIDAL 3-PHENYLISOXAZOLIN DERIVATIVES BAYER CROPSCIENCE AG (DE) 2019-08-21 EP disclosed
US-20190177271-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2019-06-13 US disclosed
CN-108558871-A Novel tricyclic compound as anticancer agent 百时美施贵宝公司 2018-09-21 CN disclosed
CN-106029663-B Tricyclic compounds as anticancer agents 百时美施贵宝公司 2018-06-01 CN disclosed
US-9585392-B2 3-phenylisoxazolin derivatives with herbicidal action BAYER CROPSCIENCE AG (DE) 2017-03-07 US disclosed
CN-106029663-A Tricyclic compounds as anticancer agents 百时美施贵宝公司 2016-10-12 CN disclosed
CN-103153945-B 1-oximino-3-phenyl-propanes HOFFMAN-LA ROCHE LTD. (CH) 2016-03-02 CN disclosed
US-20150329491-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2015-11-19 US disclosed
WO-2005085203-A1 NOVEL DIFLUOROETHOXY-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-15 WO disclosed
EP-1326853-B1 THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS WARNER LAMBERT CO (US) 2005-09-07 EP disclosed
CN-1639141-A Novel thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors WARNER LAMBERT CO (US) 2005-07-13 CN disclosed
EP-1539164-A1 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA Pharma AG (DE) 2005-06-15 EP disclosed
EP-1536798-A1 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA Pharma AG (DE) 2005-06-08 EP disclosed
WO-2004019945-A1 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2004-03-11 WO disclosed
WO-2004019944-A1 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS ALTANA PHARMA AG (DE) 2004-03-11 WO disclosed
US-20030045557-A1 Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors WARNER-LAMBERT COMPANY 2003-03-06 US disclosed
WO-2002005616-A1 NOVEL 6-PHENYLPHENANTHRIDINES ALTANA PHARMA AG (DE) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329491-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF FH, PCK2, PC ABL1 3684/4885NR4A2 4595/4885LMNA 527/4885
US-20190177271-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF FH, PCK2, PC ABL1 3684/4885NR4A2 4595/4885LMNA 527/4885
US-20200308109-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF FH, PCK2, PC ABL1 3684/4885NR4A2 4595/4885LMNA 527/4885
US-20030045557-A1 Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors PDE3A, PDE3B, PDE7A ABL1 1265/4885NR4A2 2276/4885LMNA 3287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.